Elsevier

Ageing Research Reviews

Volume 40, November 2017, Pages 31-44
Ageing Research Reviews

Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis

https://doi.org/10.1016/j.arr.2017.08.003Get rights and content

Highlights

  • Diabetics on metformin have lower morality than non-diabetics and other diabetics.

  • Diabetics on metformin have less cancer than non-diabetics and other diabetics.

  • Diabetics on metformin have less cardiovascular disease than other diabetics.

  • Metformin appears to extend health and life spans independent of its effect on diabetes.

  • Metformin may be able to extend health and lifespans in the general population.

Abstract

This systematic review investigated whether the insulin sensitiser metformin has a geroprotective effect in humans. Pubmed and Embase were searched along with databases of unpublished studies. Eligible research investigated the effect of metformin on all-cause mortality or diseases of ageing relative to non-diabetic populations or diabetics receiving other therapies with adjustment for disease control achieved. Overall, 260 full-texts were reviewed and 53 met the inclusion criteria. Diabetics taking metformin had significantly lower all-cause mortality than non-diabetics (hazard ratio (HR) = 0.93, 95%CI 0.88–0.99), as did diabetics taking metformin compared to diabetics receiving non-metformin therapies (HR = 0.72, 95%CI 0.65–0.80), insulin (HR = 0.68, 95%CI 0.63–0.75) or sulphonylurea (HR = 0.80, 95%CI 0.66–0.97). Metformin users also had reduced cancer compared to non-diabetics (rate ratio = 0.94, 95%CI 0.92–0.97) and cardiovascular disease (CVD) compared to diabetics receiving non-metformin therapies (HR = 0.76, 95%CI 0.66–0.87) or insulin (HR = 0.78, 95%CI 0.73–0.83). Differences in baseline characteristics were observed which had the potential to bias findings, although statistical adjustments were made. The apparent reductions in all-cause mortality and diseases of ageing associated with metformin use suggest that metformin could be extending life and healthspans by acting as a geroprotective agent.

Introduction

Ageing is characterised by progressive damage at a cellular and organ level as prevention and repair mechanisms begin to break down (Finkel and Holbrook, 2000, Garinis et al., 2008, Mitchell, 2008). Diseases of ageing – such as cardiovascular disease (CVD), kidney failure and cancer – are the result of the accumulation of this damage and ultimately responsible for organisms dying of old age. With the ageing population of the developed world the extension of healthspan – the period that an individual is functional and free of chronic diseases (Barzilai et al., 2016) – has been identified as an important goal both for the minimisation of human suffering and to enable healthcare systems to cope.

One drug which has been subjected to significant research as a geroprotective factor is the insulin sensitiser metformin. Metformin has been shown to extend the lifespans of model organisms (including mice and C. elegans (Anisimov et al., 2011, Anisimov et al., 2010a, Cabreiro et al., 2013)) and a number of potential mechanisms for its effects have been discussed, including decreased insulin and IGF-1 signalling (Liu et al., 2011), inhibition of mTOR (Kickstein et al., 2010, Nair et al., 2014), reducing the levels of reactive oxygen species (ROS)(Batandier et al., 2006; Zheng et al., 2012), lowering inflammation (Saisho, 2015), reducing DNA damage (Algire et al., 2012; Na et al., 2013), and the activation of AMP-activated protein kinase (AMPK)(Zhou et al., 2001). Its effect on AMPK has received particular attention as it models the intracellular mechanisms of caloric restriction (Gillespie et al., 2016, Lee and Min, 2013) – another intervention which has been found to be capable of extending the lifespans of animal models – but which is not feasible for widespread implementation in humans (Roth and Ingram, 2016). This, among other factors, has led to metformin being described as a caloric restriction mimetic (CRM) (Gillespie et al., 2016, Lee and Min, 2013, Roth and Ingram, 2016).

One aspect of metformin which makes it particularly promising for development as a geroprotective agent is that it is already being widely used in humans for a different purpose. As an insulin sensitiser metformin is a first line therapy for diabetes (Nathan et al., 2006). Through this use its potential for adverse effects and contraindications have been well characterised, and it has been found to have a broad safety profile (Rojas and Gomes, 2013) which would make it significantly quicker and easier to implement as an intervention for ageing than a previously unutilised drug.

Due to the widespread application of metformin for the management of diabetes, a large amount of data has already been collected on its effects on mortality and diseases of ageing. However, extrapolation of this research evidence to the general population is invariably confounded by the fact that the people who are currently receiving metformin have diabetes and are taking it for the treatment thereof. As such, any benefits seen could be due to improvements in diabetes control. Two analytic strategies have been attempted to overcome this limitation and gain some insight as to whether metformin could be used to improve the healthspan of the general population.

The first strategy is the comparison of the outcomes of diabetics taking metformin to the general or non-diabetic population (Bannister et al., 2014). This approach reasons that as diabetics are on average less healthy than non-diabetics, superior outcomes in the metformin/diabetic group should be a consequence of beneficial effects of metformin overcoming their generally worse health status. A weakness of this strategy is that people taking metformin could be observed to have worse or the same outcomes as non-diabetics in the presence of an actual beneficial effect of metformin due to it being masked by the detrimental effects of diabetes. The second strategy is to compare diabetics taking metformin to diabetics managing their diabetes through other means while statistically controlling for the effects of the different therapies on diabetes management (i.e. HbA1c or diabetes related doctor visits (Lin et al., 2015)). This strategy reasons that any difference in outcomes seen after adjusting for the relative effects on disease management can be attributed to metformin’s activity beyond diabetes control, and are therefore generalisable. This strategy’s weaknesses are that statistical adjustment is an imperfect process – it is always possible that residual confounding remains that could cause any differences observed − and that other antidiabetic drugs could cause harms which in comparison would appear to be beneficial effects by metformin.

However, although additional controlled, experimental research will need to be carried out, there exists a wealth of observational data that can offer evidence on whether metformin could be applied as a geroprotective agent in humans. As such, this systematic review and meta-analysis has been undertaken to identify and synthesise all studies where the effects of metformin on all-cause mortality or diseases of ageing have been compared to the general or non-diabetic population or to diabetics managing their diabetes through other means with adjustment for disease control. Numerous systematic reviews have been carried out which nominally address this review’s outcomes of interest, however those which investigate the association between metformin and all-cause mortality do so in the context of severe diseases in addition to diabetes (usually various forms of cancer) (Coyle et al., 2016, Gash et al., 2017, Li et al., 2017, Meng et al., 2017, Tang et al., 2017, Zhou et al., 2017a) and their results therefore cannot be generalised, while those that investigate the incidence of diseases of ageing do so without attempting to adjust for diabetes control (Liu et al., 2017, Ma et al., 2017, Pladevall et al., 2016, Tang et al., 2017, Zhou et al., 2017b). As such, the question of whether metformin could act as a geroprotective agent in humans has yet to be addressed in a systematic review.

Section snippets

Objective

This systematic review aimed to identify and synthesise all research on the effect of metformin on all-cause mortality and diseases of ageing which had the potential to give evidence on whether it could be used as a geroprotective factor to extend life and healthspan in the general population. It followed an a priori protocol pre-registered with PROSPERO (CRD42016036098).

Population

Studies on all-cause mortality were eligible for inclusion if they reported on adults with a minimum age of 40 years or a

Results

The initial search identified a total of 21,027 studies, which was reduced to 19,408 following the removal of duplicates. Following title/abstract screening, 260 studies were included for full-text review. Of these, 207 were excluded and 53 were included. Full search details and reasons for exclusion are given in Fig. 1. Overall, 13 included studies reported data on all-cause mortality while 49 reported on diseases of ageing.

Discussion

This systematic review has shown through meta-analysis that diabetics taking metformin have a lower rate of all-cause mortality than non-diabetic people and the general population. Our results suggest that metformin could be an effective intervention to extend the lifespans of people who do not have diabetes. This is supported by additional meta-analyses showing that diabetics taking metformin had lower rates of all-cause mortality than diabetics receiving other therapies after adjusting for

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References (95)

  • D. Sullivan et al.

    Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study

    Diabetes Res. Clin. Pract.

    (2011)
  • C.P. Wang et al.

    Differential effects of metformin on age related comorbidities in older men with type 2 diabetes

    J. Diabetes Complications

    (2017)
  • C. Algire et al.

    Metformin reduces endogenous reactive oxygen species and associated DNA damage

    Cancer Prev. Res. (Phila.)

    (2012)
  • C. Andersson et al.

    Risk of cancer in patients using glucose-lowering agents: a nationwide cohort study of 3.6 million people

    BMJ Open

    (2012)
  • E.A. Andreadis et al.

    The effect of metformin on the incidence of type 2 diabetes mellitus and cardiovascular disease risk factors in overweight and obese subjects–the Carmos study

    Exp. Clin. Endocrinol. Diabetes

    (2009)
  • V.N. Anisimov et al.

    Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo

    ABBV Cell Cycle

    (2010)
  • V.N. Anisimov et al.

    Gender differences in metformin effect on aging, life span and spontaneous tumorigenesis in 129/Sv mice

    Aging (Albany NY)

    (2010)
  • V.N. Anisimov et al.

    If started early in life, metformin treatment increases life span and postpones tumors in female SHR mice

    Aging (Albany NY)

    (2011)
  • L. Azoulay et al.

    Metformin and the incidence of prostate cancer in patients with type 2 diabetes

    Cancer Epidemiol. Biomarkers Prev.

    (2011)
  • C.A. Bannister et al.

    Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls

    Diabetes Obes. Metab.

    (2014)
  • C. Batandier et al.

    The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin

    J. Bioenerg. Biomembr.

    (2006)
  • C. Becker et al.

    Case-control analysis on metformin and cancer of the esophagus

    Cancer Causes Control

    (2013)
  • C. Becker et al.

    Metformin and the risk of head and neck cancer: a case-control analysis

    Diabetes Obes. Metab.

    (2014)
  • C. Becker et al.

    Metformin and the risk of renal cell carcinoma: a case-control analysis

    Eur. J. Cancer Prev.

    (2016)
  • E. Berard et al.

    14-year risk of all-cause mortality according to hypoglycemic drug exposure in a general population

    Eur. Heart J.

    (2011)
  • S. Bo et al.

    Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients

    Diabetes Obes. Metab.

    (2012)
  • M. Bodmer et al.

    Long-term metformin use is associated with decreased risk of breast cancer

    Diabetes Care

    (2010)
  • M. Bodmer et al.

    Use of antidiabetic agents and the risk of pancreatic cancer: a case-control analysis

    Am. J. Gastroenterol.

    (2012)
  • J.L.F. Bosco et al.

    Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

    Cancer Epidemiol. Biomark. Prev.

    (2011)
  • A. But et al.

    Assessing the effect of treatment duration on the association between anti-diabetic medication and cancer risk

    PLoS One

    (2014)
  • J.M. Campbell et al.

    Metformin and Alzheimer’s disease, dementia and cognitive impairment: a systematic review protocol

    JBI Database Syst. Rev. Implement Rep.

    (2017)
  • H.P. Chen et al.

    Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

    Gut

    (2013)
  • M. Claesen et al.

    Mortality in individuals treated with glucose-lowering agents: a large, controlled cohort study

    J. Clin. Endocrinol. Metab.

    (2016)
  • N. Ekstrom et al.

    Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register

    BMJ Open

    (2012)
  • J.M. Evans et al.

    Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

    Diabetologia

    (2006)
  • T. Finkel et al.

    Oxidants, oxidative stress and the biology of ageing

    Nature

    (2000)
  • J.S. Floyd et al.

    Case-control study of oral glucose-lowering drugs in combination with long-acting insulin and the risks of incident myocardial infarction and incident stroke

    Pharmacoepidemiol. Drug Saf.

    (2016)
  • G.A. Garinis et al.

    DNA damage and ageing: new-age ideas for an age-old problem

    Nat. Cell Biol.

    (2008)
  • K.J. Gash et al.

    Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy

    Br. J. Cancer

    (2017)
  • A.A. Ghotbi et al.

    Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial

    Diabetes Care

    (2013)
  • Z.E. Gillespie et al.

    Better living through chemistry: caloric restriction (CR) and CR mimetics alter genome function to promote increased health and lifespan

    Front. Genet.

    (2016)
  • C.B. Giorda et al.

    Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study

    Eur. J. Cardiovasc. Prev. Rehabil.

    (2011)
  • M.E. Goossens et al.

    Influence of metformin intake on the risk of bladder cancer in type 2 diabetes patients

    Br. J. Clin. Pharmacol.

    (2015)
  • E.O. Gosmanova et al.

    Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus

    Am. J. Med. Sci.

    (2008)
  • D.M. Hartung et al.

    Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a medicaid claims-based case-control study

    Pharmacotherapy

    (2005)
  • A.M. Hung et al.

    Kidney function decline in metformin versus sulfonylurea initiators: assessment of time-dependent contribution of weight, blood pressure, and glycemic control

    Pharmacoepidemiol. Drug Saf.

    (2013)
  • S.P. Jansson et al.

    Effects of fasting blood glucose levels and blood pressure and treatment of diabetes and hypertension on the incidence of cardiovascular disease: a study of 740 patients with incident Type 2 diabetes with up to 30 years' follow-up

    Diabet. Med.

    (2014)
  • Cited by (286)

    View all citing articles on Scopus
    View full text